The first year fellows are almost here, and we are so thrilled. Welcome! We were feeling incomplete without you. And congratulations to our senior fellows on finishing the year strong. The future of hematology and oncology is oh so bright! ✨️

In metastatic #breastcancer, sacituzumab govitecan given after trastuzumab deruxtecan was linked to ⬇️ PFS across all subtypes. Real-world data published in JNCI show differences in outcomes by type. academic.oup.com/jnci/advance-a… Smilow Cancer Hospital YaleBreastCancer Maryam Lustberg MD, MPH, FASCO

Excited to have joined Eric Winer, MD and Etienne for this discussion on medical oncology training, the future of oncology, and more! 🎙️🩺 Yale Hematology Oncology Fellows Yale Cancer Center YaleBreastCancer

Future of Cancer Care and the Next Generation of Oncologists – Yale Cancer Center Yale Cancer Center Yale Hematology Oncology Fellows Müschen Lab Nicole Casasanta, MD Eric Winer, MD oncodaily.com/voices/future-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews CancerWorld

GLSI-100 has been granted FDA Fast Track designation for preventing HER2-positive breast cancer recurrence, showing an 80% reduction in a trial. Read more using the link in the replies below.

The U.S. FDA has approved imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with ER+, HER2–, ESR1-mutated advanced or metastatic #BreastCancer that has progressed after at least one line of endocrine therapy. buff.ly/weJEKUh The approval

Presented at #ESMO25: In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). Full ASCENT-03 phase 3 trial results: nej.md/4ncuUCV ESMO - Eur. Oncology

📌evERA in HR+ MBC tx with prior CDK4/6i randomized to giredestrant + everolimus vs SOC ET + everolimus 🔹ESR1m PFS 9.99 vs 5.45 m, p<0.0001 🔹Overall population PFS 8.77 vs 5.49 m, p<0.0001 ➡️ Excellent option for HR+ MBC post CDK4/6i especially in ESR1m #ESMO25

VIKTORIA-1 in PIK3CAwt HR+ MBC with prior CDK4/6i randomized to gedatolisib + palbociclib + fulvestrant (F) vs geda + F vs F 🔹triplet vs F PFS 9.3 vs 2 m p <0.0001 🔹doublet vs F PFS 7.4 vs 2 m p <0.0001 ➡️geda requires weekly visits 🔍Is effect PIK3CA or mTOR?

💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management & so much more ✨Thank you Lynn Sage Breast Cancer Foundation for the travel award! 💐#LSBC25 Lurie Cancer Center Stephanie A. Haddad, DO Yale Hematology Oncology Fellows

📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing goals of de-escalation in low risk, escalation in high risk, & individualized treatment in intermediate risk. Thankful for the opportunity to attend! ✨#LSBCS25 Lynn Sage Breast Cancer Foundation Lurie Cancer Center Harold J. Burstein, MD, PhD, FASCO

🚨Huge news, can’t wait to see the data of the first oral SERD showing iDFS improvement in early stage HR+ breast cancer!

🔔🚨Clinical trial alert! Enrolling patients with HER2-0 metastatic breast cancer to receive T-DXd with no upper limit of prior lines! medicine.yale.edu/ycci/clinicalt…